50 results about "Carbapenem resistant" patented technology

The invention discloses a kit and a detection method for detecting carbapenem-resistant enterobacteriaceae (CRE). The detection primer pair in the present invention is selected from one or several pairs of KPC detection primer pair, NDM detection primer pair, IMP detection primer pair, VIM detection primer pair and OXA-48 detection primer pair. The kit described in the present invention covers common carbapenem-resistant genes, with a minimum detection of 1 copy/uL. The detection method of the invention has the characteristics of good sensitivity, high specificity, accurate quantification, etc., and has important clinical significance for the detection and monitoring of the increasingly severe CRE epidemic outbreak.

The invention discloses an antimicrobial peptide, which has the sequence as follow: Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-X1-X2-Arg-Arg-Leu-Trp-Gly-Ala, wherein the X1 is selected from Lys, Arg, Trp, Leu, Phe and Tyr; and the X2 is selected from Trp, Arg, Lys, Phe, Ser and His. The antimicrobial peptide has an obvious inhibiting effect on methicillin-resistant s. aureus, vancomycin-resistant enterococci, carbapenem-resistant pseudomonas aeruginosa and carbapenem-resistant klebsiella pneumoniae, and has lower hemolytic activity, good stability, high antimicrobial activity, and an efficient broad-spectrum bacteriostatic action.

The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.

The invention discloses a biological reagent for treating carbapenems-resistant acinetobacter baumannii infection. The reagent is a protein solution of lyase of a bacteriophage AB3. A preparation method includes separating and purifying the bacteriophage AB3, extracting a bacteriophage AB3 genome, subjecting deoxyribonucleic acid (DNA) of the bacteriophage AB3 to enzyme digestion analysis, performing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of capsid protein of the bacteriophage AB3, amplifying a lyase gene of the bacteriophage AB3, constructing a prokaryotic expression carrier and expressing and purifying the lyase gene. By means of a method that the prokaryotic expression carrier is constructed to express and purify the lyase gene of the bacteriophage AB3, the biological reagent can be used for clinically treating the carbapenems-resistant acinetobacter baumannii infection, and the biological reagent has the advantages of being high in specificity, fast in effects and capable of being used as a novel antibacterial agent and has unique advantages and good application prospects.

The invention discloses application of 2,6-bis(2-benzimidazolyl) pyridine in preparation of a carbapenem-resistant pseudomonas aeruginosa infection drug. Through circular dichroism, fluorescent real-time quantitative PCR and other methods, it is found that 2, 6-bis (2-benzimidazolyl) pyridine can form a G-quadruplex structure with a core sequence of a MexA gene in pseudomonas aeruginosa, thereby inhibiting expression of the MexA gene. A susceptibility testing verifies that 2, 6-bis (2-benzimidazolyl) pyridine can reduce the drug resistance of carbapenem-resistant pseudomonas aeruginosa to meropenem. When the usage amount of the 2, 6-bis (2-benzimidazolyl) pyridine is 5 <mu>M, the minimum inhibitory concentration of the carbapenem-resistant pseudomonas aeruginosa strain can be reduced to 2<mu> g/ml, and the effect of treating carbapenem-resistant pseudomonas aeruginosa infection by using meropenem is achieved.

The invention discloses a method for recognizing carbapenems-resistant Escherichia coli by using the pattern recognition technology. The method for recognizing the carbapenems-resistant Escherichia coli by using the pattern recognition technology comprises the following steps: a, collecting Escherichia coli; b, extracting metabolites and polypeptides from the Escherichia coli; c, performing Orbitrap-MS analysis and detection; d, performing Orbitrap-MS data processing and analysis; and e, using an R language software and an own program to perform pattern recognition and analysis on the data. The powerful statistical capabilities of the R language software is used for processing large amounts of data obtained from the high-resolution Orbitrap-MS, and the pattern recognition and analysis is carried out on mass spectrometry data of carbapenems medicine-resistant Escherichia coli strains and sensitive Escherichia coli strains, so that the fast and accurate recognition of the carbapenems-resistant Escherichia coli strains and the sensitive Escherichia coli strains is realized. Meanwhile, the compounds with significant differences at the statistics are found, so that a theoretical basis for studying the differences between the carbapenems-resistant Escherichia coli strains and the sensitive Escherichia coli strains and elucidating the resistance mechanisms of Escherichia coli is provided.

The invention relates to a polyketide synthase Preu3-delta CMeT and application thereof in preparation of orsellinic acid, and belongs to the technical field of molecular biology and biochemistry. The amino acid sequence of the polyketide synthase Preu3-delta CMeT is as shown in SEQ ID NO.1, and the polyketide synthase Preu3-delta CMeT is constructed by taking polyketide synthase Preu3 derived from phorbia fungi as a material and knocking out a CMeT structural domain of the polyketide synthase Preu3-delta CMeT on the basis of a combined biosynthesis technology; the polyketide synthase Preu3-delta CMeT is transferred into saccharomyces cerevisiae to successfully obtain a mutant strain capable of efficiently producing the orsellinic acid; and the prepared orsellinic acid is taken as an object, the inhibitory activity of the orsellinic acid on clinical drug-resistant bacteria and crop pathogenic fungi is researched, and the orsellinic acid is found to have a very strong antagonistic effect on carbapenem-resistant pseudomonas aeruginosa, and the MIC is 12.5 [mu]g/mL. The polyketide synthase Preu3-delta CMeT greatly enriches the production sources of the orsellinic acid, and has important scientific value and application prospect for expanding the derivatization approach of the orsellinic acid and researching and developing a novel antibacterial agent.

The invention relates to a novel clinical application of minor radix buplenri granules. The invention further discloses an application of the minor radix buplenri granules or the minor radix buplenrigranules and amikacin in preparation of drugs for preventing and treating carbapenem-resistant klebsiella pneumoniae infection. It is found that the minor radix buplenri granules can be combined withthe amikacin in antibiotics to improve the antibacterial effect on CRKP, have the sensitization effect and can serve as a natural antibiotic sensitizer. The combined use of the minor radix buplenri granules and the amikacin can enhance the clinical treatment on the CRKP infection, and especially has good antibacterial effect and sensitization effect on bacterial pneumonia caused by the CRKP.

The present invention relates to a culture medium comprising a carbapenem, a carbapenemase activator and a M-type penicillin. It also relates to a method for detecting carbapenem-resistant bacteria in a test sample using said culture medium.

The invention discloses a reagent kit for screening carbapenem resistant enterobacteria (CRE) from an excrement and urine sample and a method for screening the carbapenem resistant enterobacteria (CRE). The reagent kit comprises 5ml of excrement and urine and broth bacterium increasing fluid and a medicine-containing plate, wherein the excrement and urine and broth bacterium increasing fluid comprises 0.5wt% of sodium chloride, 0.5wt% of yeast powder and 1wt% of phytone, a substrate is bacteria-free water, the PH is 7.0, and high-pressure sterilization is performed at 121 DEG C for 15min; andthe medicine-containing plate is a China blue plate which comprises meropenem, and the concentration of the meropenem is 0.3 [mug]/m. A two-step method is used for screening, firstly, bacterium increasing is performed for the first time to obtain medicine-resistance bacteria, and secondly, screening is performed with a medicine plate to obtain medicine-resistance single colonies. The method is convenient to use, the interference of infectious microbes of fungi is greatly reduced, the screening positive rate is high, and the method can be widely applied to clinical laboratories and can meet CRErapid diagnosis requirements of clinical treatment.

The invention proposes routine treatment of patients, particularly those admitted to an ICU, with Vitamin D and liposomal glutathione for prophylaxis and treatment against Group B Streptococcus and Carbapenem-resistant enterobacteriaceae, and biomarkers to measure effectiveness of treatment. Further, because the method of treatment bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more antibiotic- and/or carbapenem resistant strains is downgraded.

The invention discloses a chromogenic medium of carbapenem resisting klebsiella, and belongs to the field of disease microorganism culturing and identification. The culture medium comprises 4-6 partsby weight of sodium chloride, 0.1-0.3 part by weight of magnesium sulphate, 0.5-1.5 parts by weight of ammonium dihydrogen phosphate, 0.5-1.5 parts by weight of dipotassium hydrogen phosphate, 4-6 parts by weight of sodium citrate, 13-17 parts by weight of agar, 0.06-1 part by weight of bromothymol blue, 9-11 parts by weight of myo-inositol, 0.001-0.003 part by weight of meropenem and 900-1100 parts by weight of water. The culture medium is good in specificity, quickly cultures the carbapenem resisting klebsiella, and facilitates infection control of the carbapenem resisting klebsiella in hospitals.

The present disclosure relates to a compound represented by Chemical Formula 1, a probe for detecting antibiotic-resistant bacteria, which includes the compound, a composition containing the compound, a kit including the compound and a method for detecting antibiotic-resistant bacteria. A compound probe having a carbapenem structure and including a linker and a fluorophore can detect beta-lactamase or carbapenemase at high sensitivity and, therefore, can be applied to various biochemical researches. In addition, the compound probe can clinically detect carbapenemase-producing antibiotic-resistant bacteria and allows molecular diagnosis of antibiotic-resistant bacterial infectious diseases and analysis of antibiotic-resistant bacteria from a target sample at high sensitivity. Therefore, it can be effectively used for medicinal uses such as in-vitro diagnosis.

The invention belongs to the technical field of clinical microbiological detection, and particularly relates to a hospital environment carbapenem-resistant klebsiella pneumoniae detection rate high detection method, which comprises the following steps: S1, sampling: sampling the surface of a detected object by using a sterilization specification board and a cotton test piece; the carbapenem-resistant klebsiella pneumoniae on the surface of a to-be-detected object is adsorbed by a cotton test piece soaked with nutrient broth, and is cultured in a constant-temperature box at 35 +/-1 DEG C for 24 hours, so that the growth quantity of the carbapenem-resistant klebsiella pneumoniae is greatly increased, and meanwhile, bacteriostats are generated to inhibit the growth of other gram-positive bacteria, so that the detection sensitivity is greatly improved. The carbapenem-resistant klebsiella pneumoniae can be detected through special detection methods in the steps S1 to S5, and different from a traditional detection mode, the detection rate of the carbapenem-resistant klebsiella pneumoniae is increased, a basis is provided for prevention and control work of hospitals, the occurrence rate of the carbapenem-resistant klebsiella pneumoniae in the hospitals is reduced, and the clinical application prospect is broad. And the workload is reduced to a certain extent.

The invention discloses application of an N-heterocyclic carbene selenium-gold compound in preparation of a novel antibacterial drug resistant to carbapenem acinetobacter baumannii infection, and belongs to the technical field of drug preparation. According to the N-heterocyclic carbene selenium-gold compound, selenium-containing imidazole N-heterocyclic carbene selenium is used for replacing a thiosaccharide ligand in a gold nofen structure; the reaction activity of Au-Se in the N-heterocyclic carbene selenium-gold compound is higher than that of an Au-S bond, so that the Au-S bond in a Jinnofen structure can be prevented from being easily damaged by reducing mercaptan to a certain extent; and toxic and side effects are caused by metabolism before reaching a target spot. In-vitro antibacterial activity shows that IC50 of the compounds H7 and H8 in inhibition of carbapenem-resistant acinetobacter baumannii is 3.34 mu M and 4.67 mu M, MIC of the same are both 10 mu M, and MBC of the same are both 20 mu M. The animal in-vivo administration also shows a good anti-drug-resistant bacterium effect, which proves that the compound can significantly prolong the survival time of mice infected by drug-resistant bacteria, and has important practical application value.

The application of a sulbactam and ceftazidime composition in the preparation of a drug for treating a carbapenem-resistant antibiotic Acinetobacter baumannii infection, characterized in the following: by mass, the amount of ceftazidime used in the sulbactam and ceftazidime composition comprising 10% to 90% of the amount of sulbactam used.